October 30, 2013
Dr. Dickerson is awarded a legislative achievement for his work in prostate cancer. Watch the video
August 2, 2013
Dr. Dickerson is awarded a legislative achievement for his work in prostate cancer. This article from the FDA offers some great tips and info about how to do just that while still enjoying some fun in the sun!
June 24, 2013
Anova Cancer Care Hits Major Milestone by Treating 400 Denver Area Prostate Cancer Patients with the CyberKnife
May 15, 2013
US News & World Report: Dr. Gregg Dickerson 2012 ‘Top Doc’
Vitals: Dr. Gregg Dickerson 2012 ‘Top Doc’
Watch the video
April 30, 2013
Pre-Publication Trial Results Demonstrate Safety and Effectiveness of CyberKnife Prostate Cancer Treatment
April 17, 2013
ASTRO: Coverage for Stereotactic Body Radiation Therapy (SBRT)
Download: Read more
November 29, 2012
Anova Cancer Care Brings Future of Lung Cancer Treatment to Denver
October 29, 2012
Lung Cancer Diagnosis Improved with Gene Testing Plus Bronchoscopy.
August 28, 2012
Anova Cancer Care Selected for National Prostate Cancer Study.
August 23, 2012
Prostate Cancer Survival Rate Improved After PSA Introduced in US.
August 2, 2012
Accuray announces first CyberKnife in South America!
July 2, 2012
Anova Cancer Care donates to the Waldo Canyon Fire.
Download: Read more
June 15, 2012
Prostate coverage update! Cigna has officially updated their medical policy to cover CyberKnife for prostate cancer! Click on the following link to download the updated policy!
Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) – (0110) (Radiation Therapy Related CP).
June 12, 2012
Denver CyberKnife is now Anova Cancer Care.
Download: Read more
January 20, 2012
Prostate Update! TrailBlazer (the Medicare contract for Colorado) has APPROVED prostate CyberKnife treatment for all patients enrolled in a clinical trail! Please contact our center for additional information!
Download: Updated policy!
Landmark Lung Cancer Research Study Approves Only Site in the Denver Metro area
August 1st, 2011
Anova Cancer Care obtains IRB approval as the only site in Colorado to participate in phase III lung cancer trail comparing radio-surgery to surgery.
April 15, 2010
Lone Tree, CO – Anova Cancer Care radiation oncologist Dr. Gregg Dickerson, and Cardiovascular Surgical Professionals thoracic surgeon, Dr. Richard Parker, have teamed up as the principal investigators for the clinical trial comparing two standard treatments for early-stage NSCLC (Non-Small Cell Lung Cancer), the most common form of lung cancer.
The STARS (Stereotactic Radiosurgery vs. Surgery) trail will compare the three-year survival rate of patients who undergo a lobectomy, a surgical procedure to remove the tumor, versus CyberKnife treatment, a unique stereotactic body radiotherapy (SBRT) technique that precisely tracks and focuses the radiation on the tumor. SBRT is now an accepted treatment for medically inoperable patients with stage I NSCLC and patients with operable stage I lung cancer who are entered on clinical protocols. The purpose of this study is to conduct a phase III randomized prospective study to compare CyberKnife SBRT with surgery, the current standard of care for stage I operable NSCLC.
“SBRT for lung cancer has demonstrated excellent results for patients with medically inoperable lung cancer,” said Dr Dickerson. “In single institution, non-randomized studies for operable lung cancer, SBRT has shown to maintain at least equivalent results to surgery. Patients will be the real beneficiaries from continued development of treatment alternatives for their conditions.”
NSCLC typically advanced more slowly than small cell lung cancer. Smoking is the most common cause of lung cancers, including up to 85 percent of NSCLC cases. Anova Cancer Care is the only facility in Colorado to participate in STARS clinical trial, which is led by M.D. Aderson Cancer Center in Houston, Texas and is enrolling patients in more than 20 centers around the world.
To qualify, prospective participants must be 18 years or old and have Stage I NSCLC. Additional diagnostic testing will be required to determine qualification. Once accepted into the study, participants will be randomly selected to receive surgery or radiation via the CyberKnife; both treatments are FDA approved for lung cancer. Participants will be followed for three years after treatment, which will include follow-up consultations and additional treatment, if needed.
For additional information about participating in the study, please call (303) 396-1400.
About Anova Cancer Care (www.anovacancercare.com)
Anova Cancer Care is a independent, free-standing radiation therapy center dedicated to treating patients with tumors using image-guided radiosurgery. Anova Cancer Care treats the brain, spine, lung, prostate, pancreas, liver, head and neck, and other conditions throughout the body. Many patients are treated with the CyberKnife for conditions that have been deemed inoperable or from areas that have previously received the maximum level of radiation. The range, accuracy, and precision of the CyberKnife system can help target areas that may not be suitable for treatments with traditional surgery, radiation therapy or other radiosurgery systems. The center works with Medicare and with all major commercial insurance companies.